Business Wire

GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%

Share

GENECAST, cancer diagnostics company through liquid biopsy, today announced the launch of ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005007/en/

GENECAST, cancer diagnostics company through liquid biopsy, launched ADPSTM BRAF, EGFR, JAK2 mutatio ...

GENECAST, cancer diagnostics company through liquid biopsy, launched ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO). ADPS(TM) BRAF Mutation Test Kit (RUO) (Photo: Business Wire)

Especially ADPSTM BRAF mutation test kit has 0.0001% detection sensitivity which is 100 times higher than any other products, as well as EGFR and JAK2 mutation kits have the high detection sensitivity of 0.01%.

Detection sensitivity is the most important indicator of determining the accuracy of liquid biopsy. According to Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev 2017; 42:14-21, high detection sensitivity of 0.01% or less is important for early diagnose cancer using liquid biopsy.

ADPSTM BRAF mutation test kit can diagnose 4 BRAF mutations that are mainly found in thyroid cancer and melanoma with 0.0001% of detection sensitivity -meaning 3/3,000,000 mutation genes can be detected. It is 100 times better than ddPCR which previously had the highest detection sensitivity. Since ADPS technology is based on qPCR, it can reduce the expense and shorten clinical test time.

GENECAST is speeding up certification and approval procedures so that the kits can be used in the clinical fields. ADPSTM EGFR Mutation test kit which diagnoses EGFR- the most common cancer mutation in NSCLC, is in a process of FDA PMA. This is the world’s second trial as liquid biopsy cancer diagnostic kit. GENECAST plans to get FDA PMA approval by the second half of 2021. Also will prepare for CE-IVD after getting ISO 13485:2016 certification by this September.

“ADPS Oncology kits will show the possibility of precision medicine in the 1st and 2nd stage cancer patients,” said Ph.D. ByungChul Lee, CTO of GENECAST. “Yet, not becoming complacent, we will actualize early cancer diagnosis through liquid biopsy by continuously developing diverse cancer kits and new technologies.”

GENECAST will launch KRAS, NRAS, PIK3CA, pTERT, IDH1, IDH2 mutation test kits(RUO) by the end of 2019, and complete certification of CE-IVD for 9 Oncology kits by the first half of 2020.

About GENECAST

GENECAST is a genetic testing start-up with liquid biopsy, specialized in monitoring cancer with original Allele-Discriminating Priming System (ADPS) that boasts an unprecedented sensitivity of 0.0001%. GENECAST’s mission is to make cancer as commonly curable disease by straightly face cancer with the highest detection sensitivity. ADPSTM EGFR mutation test kit is in the process of approving FDA PMA Class3 and aims to get approval by 2021. Besides ctDNA diagnostic technology, researchers are continuously developing new diagnostic technologies to fulfill the mission.

Contact information

GENECAST
Communication team
+82-2-2157-3150
Soobin Shin
comm@igenecast.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Statement From The We Company17.9.2019 05:57:00 EESTPress release

The We Company (the “Company”) has issued the following statement: “The We Company is looking forward to our upcoming IPO, which we expect to be completed by the end of the year. We want to thank all of our employees, members and partners for their ongoing commitment.” This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Copies of the preliminary prospectus relating to the offering, when available, may be obtained from the Company at 115 West 18th Street, New York, New York 10011. View source

PSE plans to become part of Siemens17.9.2019 03:00:00 EESTPress release

Process Systems Enterprise (PSE), the leading supplier of Advanced Process Modelling (APM) software and services, today announced that it plans to be acquired by Siemens AG in a transaction scheduled to close in Q4 2019. The 160-strong PSE operation will be integrated into the Process Automation Business Unit of Siemens Digital Industries. The current PSE management team will remain in place. PSE’s advanced process models are used within digital R&D, design and operations in the process industries to help make fast, safe and more efficient decisions through rapid and effective exploration of the decision space. The technology is widely used in the chemicals, petrochemicals, pharmaceuticals and food industries to accelerate innovation, improve process design and operation, streamline R&D and manage technology risk. PSE’s model-based solutions span the entire process lifecycle via a unified and integrated set of tools. These strongly complement the Siemens portfolio in the process indust

Velodyne Executive Addresses Why Lidar is Necessary for Safe Vehicle Automation at IAA 2019 Conference17.9.2019 01:19:00 EESTPress release

Marta Hall, President and Chief Business Development Officer of Velodyne Lidar, Inc. will address the future of vehicle safety at the IAA 2019 Conference in Frankfurt. Hall’s presentation will highlight the development of advanced, cost-effective lidar technology for advanced driver assistance systems (ADAS) and autonomy, particularly to protect pedestrians, assist drivers and save lives. The event will take place at Velodyne’s booth (Hall 8.0, Booth A13) on September 18 at 11:00 a.m. CEST (GMT+2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190916005913/en/ Marta Hall, President and Chief Business Development Officer of Velodyne Lidar, Inc., will address why lidar is necessary for safe vehicle automation at the IAA 2019 Conference. (Photo: Velodyne Lidar) “There are dozens of companies working on autonomous vehicles. Incredible possibilities have opened as a result of the engineering efforts towards autonomy. In rolling

Virgin Voyages Reveals High-fashion Uniform Collection Designed by Gareth Pugh With a Star-studded Celebration at London Fashion Week16.9.2019 23:32:00 EESTPress release

Virgin Voyages, the new lifestyle brand that is shaking up the travel industry, has unveiled pieces from its stylish new uniform collection designed by maverick British fashion designer Gareth Pugh. The collection was showcased in a star-studded event during London Fashion Week last night. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190916005874/en/ Virgin Voyages Reveals High-fashion Uniform Collection Designed by Gareth Pugh With a Star-studded Celebration at London Fashion Week. (Photo: Business Wire) The event at London's Royal Opera House featured a live surprise performance by Christina Aguilera. Christina Aguilera was dressed by Gareth Pugh in original designs featuring the capsule collection’s signature hues of red and black. “People are at the heart of all of our Virgin companies and when our people feel their best, they help make guest experiences the best they can be,” said Sir Richard Branson, founder of the V

VALBIOTIS Presents Positive Results From a Study on TOTUM-63, Active Substance of VALEDIA®, Conducted by the CarMeN Laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)16.9.2019 18:40:00 EESTPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019 in Barcelona, Spain. This preclinical study evaluated the effect of TOTUM-63 on the secretion of certain hormones which play a fundamental role in glucose metabolism. In a murine model of metabolic disease, TOTUM-63 completely corrected insulin, glucagon and GLP-1 (Glucagon-Like Peptide-1) concentrations in the portal vein, in response to a glucose intake. These three hormones are central to the regulation of blood glucose. This study confirms, via an independent laboratory, the effects already demonstrated1 on blood glucose and weight by TOTUM-63, the a

IFF Celebrates Opening of New Innovation Center in Holmdel’s Historic Bell Works16.9.2019 18:00:00 EESTPress release

Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition and ingredients today opens the doors to its Home & Fabric Care Innovation Center at Bell Works in Holmdel, New Jersey. To mark the occasion, Chairman and CEO Andreas Fibig will be joined by business leaders, IFF employees, and Holmdel community members for a ribbon-cutting ceremony. IFF’s Innovation Center is a 60,000 square-foot research and development hub with 32 state-of-the art evaluation spaces and labs. It is the new home for 120 IFF employees. Designed to foster co-creation and spark creativity, IFF’s space within Bell Works not only provides employees with collaborative areas and an office-wide open floor plan, but also draws inspiration from IFF’s newly launched purpose and brand identity. IFF has a proud history of innovative firsts, and its opening in Holmdel connects the Company’s legacy with that of Bell Works, which is the home of so many breakthrough devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom